Common Contracts

Development and licensing agreement for oral formulation of insulin

Development and Licensing Agreement • January 31st, 2022 • New York

• Contract Type
  Development and Licensing Agreement
• Filed
  January 31st, 2022
• Jurisdiction
  New York

Emisphere and Novo Nordisk entered an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins using Emisphere's Eligen® Technology.